Xie Dan, Sham Jonathan S T, Zeng Wei-Fen, Lin Han-Liang, Bi Jiong, Che Li-Hong, Hu Liang, Zeng Yi-Xin, Guan Xin-Yuan
Cancer Center, Sun Yat-Sen University, Guangzhou 510275, China.
Hum Pathol. 2005 Jul;36(7):777-83. doi: 10.1016/j.humpath.2005.05.007.
AIB1, a member of the steroid receptor coactivator 1 family, has been cloned on 20q12 and is a candidate oncogene in human breast cancer. It is commonly amplified and overexpressed in several types of human cancers. In this study, we examined the expression of AIB1, as related to clinicopathologic features, in 85 human colorectal cancers (CRCs). The status of the number of AIB1 copies, p53 expression, and DNA ploidy was also analyzed. The overexpression of AIB1 was detected in 35% of CRCs. Amplification of AIB1 was observed in 10% of CRCs. In addition, the overexpression of AIB1 was observed more frequently in CRCs in later clinical stages (T3 N1 M0/T3 N0 2M1), compared with that in T3 N0 M0 stage (P < .05). These results suggest that overexpression of AIB1 might provide a selective advantage for the developmental growth and/or progression of subsets of CRCs. In addition, a significant correlation (P < .05) of overexpression of AIB1 with p53 overexpression as well as with aneuploid DNA content was observed in these CRCs. The overexpression of p53 was also correlated significantly with CRC DNA ploidy (P < .05). Furthermore, there was a substantial population of CRCs showing overexpression of both AIB1 and p53 protein and all had aneuploid DNA content; most of these were in the later clinical stage. These findings suggest a possible convergence of AIB1 with a pathway involving p53, which might induce chromosomal instability and affect the clinical phenotype of a subset of CRCs.
AIB1是类固醇受体辅激活因子1家族的成员，已在20q12上克隆，是人类乳腺癌中的一个候选癌基因。它在几种类型的人类癌症中通常会扩增并过度表达。在本研究中，我们检测了85例人类结直肠癌（CRC）中AIB1的表达及其与临床病理特征的关系。还分析了AIB1拷贝数状态、p53表达和DNA倍性。在35%的CRC中检测到AIB1的过度表达。在10%的CRC中观察到AIB1的扩增。此外，与T3 N0 M0期相比，AIB1的过度表达在临床晚期（T3 N1 M0/T3 N0 2M1）的CRC中更频繁地观察到（P <.05）。这些结果表明，AIB1的过度表达可能为CRC子集的发育生长和/或进展提供选择性优势。此外，在这些CRC中观察到AIB1的过度表达与p53的过度表达以及非整倍体DNA含量之间存在显著相关性（P <.05）。p53的过度表达也与CRC DNA倍性显著相关（P <.05）。此外，有相当一部分CRC显示AIB1和p53蛋白均过度表达，且均具有非整倍体DNA含量；其中大多数处于临床晚期。这些发现表明AIB1可能与涉及p53的途径汇聚，这可能会诱导染色体不稳定并影响一部分CRC的临床表型。
